News · 2026-06-04
FDA Semaglutide Compounding Update: 2026
The FDA's April 2026 proposal to exclude semaglutide from the 503B bulks list, and what it means for online programs.
Quick Answer
On April 30, 2026 the FDA proposed excluding semaglutide, semaglutide, and liraglutide from the 503B bulks list, citing no clinical need. With the shortage already resolved, this would close the main remaining large-scale compounding pathway if finalized.
For the full breakdown and primary-source links, see the regulatory explainer. Related: provider directory, 503B definition, what the FDA says.
Bottom Line
The trajectory is toward limiting large-scale compounding. Follow the FDA docket and verify any program’s pharmacy pathway.
Compounded semaglutide is not FDA-approved as a finished drug product. Compounded medications may be prescribed only when clinically appropriate and must be evaluated by a licensed prescriber. Branded medications such as Wegovy and Ozempic are FDA-approved products; compounded semaglutide is different and should not be described as FDA-approved, “generic Wegovy,” or “generic Ozempic.”